ArticlePharmacology research & perspectives2017

Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects.

Leonie van Meer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.